Clinical & Research Rationale

Clinicians frequently must initiate antibiotics before culture results establish whether viable bacteria are present in the suspected compartment. ISOKEM-X is being developed to assess bacterial activity directly in patient-derived specimens, including blood, urine, and cerebrospinal fluid, providing earlier evidence to support antibiotic decisions while conventional microbiology is pending. Its intended role is to supplement clinical assessment without delaying urgent treatment.

Identifying a bacterium does not, by itself, establish its susceptibility to a particular antibiotic. Standard minimum inhibitory concentration (MIC) testing reports a growth-inhibition endpoint, not the full time course of bacterial suppression.

ISOKEM-X is designed to compare the onset, magnitude, and persistence of bacterial suppression following antibiotic exposure in patient-derived specimens. The goal is to provide functional evidence for antibiotic selection beyond organism identity, while conventional susceptibility testing is pending.

Bacterial urease generates ammonia from urinary urea, raising urine pH and promoting struvite crystallization. These processes can contribute to catheter encrustation, infection stones, and obstruction, creating problems that require more than antibiotic treatment alone.

ISOKEM-X’s kinetic phenotyping application is designed to investigate whether the onset, rate, and persistence of bacterial activity identify patterns associated with these complications. The clinical objective is to inform earlier evaluation for obstruction, catheter-related problems, or the need for urologic intervention.

Persistent infection can reflect ineffective antibiotic coverage, an infected device, or an undrained collection such as an abscess. These possibilities require different responses, including changing treatment, removing a device, or draining an infection source.

Serial ISOKEM-X measurements are intended to assess whether bacterial activity decreases, persists, or returns during treatment, adding evidence for antibiotic and source-control reassessment.

Pancreatitis, major trauma, and postoperative inflammation can produce findings that resemble infection. Fever, tachycardia, and elevated inflammatory markers, including C-reactive protein (CRP) and procalcitonin, do not establish that viable bacteria are present.

I-TRACE is being developed to add direct evidence of bacterial activity to this distinction, supporting antibiotic decisions when the clinical picture remains ambiguous.

Immunocompromised patients face a diagnostic paradox: the defenses that protect against infection also generate many of its recognizable warning signs. In chemotherapy-associated neutropenia, serious infection can progress with muted local inflammation, including little erythema or swelling.

I-TRACE targets bacterial activity rather than the strength of the immune response, with the goal of improving recognition in patients whose presentation understates their risk.

Mean arterial pressure, serum lactate, and oxygen requirements help describe how critically ill a patient is; they do not directly establish whether viable bacteria remain.

Serial I-TRACE measurements are intended to assess whether bacterial activity decreases, persists, or returns during treatment, adding evidence when clinicians must reassess antibiotic effectiveness or investigate an unresolved infection source.

An unresponsive, confused, or intubated patient may be unable to report symptoms or identify an infection source. Hypotension and altered consciousness demand immediate action but do not establish an infectious cause.

I-TRACE’s intended bedside role is to provide earlier bacteria-directed information during emergency evaluation, alongside resuscitation and empiric treatment, without waiting for culture growth.

In extraction-based LC–MS and GC–MS workflows, measuring intracellular chemistry requires stopping activity in the sampled material, extracting metabolites, and analyzing the resulting preparation. Each additional time point requires another sample and another processing cycle.

Reaction kinetics are therefore reconstructed from separately processed samples. Capturing inhibition, recovery, or a short-lived response increases both sample consumption and analytical workload. Metabolite concentration alone does not resolve this problem: the same concentration can accompany different rates of production and consumption.

KEMFlux is designed to measure compatible biochemical reactions directly and continuously through their stoichiometrically coupled volatile products, without repeated destructive sampling of the active system.

KEMFlux’s drug-response application targets inhibition onset, magnitude, duration, and recovery within the same active system, supporting comparison of compounds and exposure schedules.

KEMFlux’s cancer-research application targets pathway responses during treatment. The objective is to distinguish functional suppression from cell loss and investigate persistent or returning activity, using reaction kinetics alongside independent viability measurements.

KEMFlux’s mitochondrial application targets selected oxidative reaction kinetics during drug exposure, oxygen limitation, and nutrient shifts, supporting investigation of changes in substrate utilization.

KEMFlux’s bioprocess application targets the onset, magnitude, and persistence of reaction responses to feeding and aeration changes, supporting feed-strategy comparison and investigation of declining process performance.